Review the side-effects of Triptorelin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment. Background: Medical castration using gonadotropin-releasing hormone (GnRH) ...

Women with polycystic ovary syndrome have less increase in follicle-stimulating hormone after triptorelin administration during in vitro fertilization than women without PCOS, according to data from ...

Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with ...

Among the numerous medications for achieving medical castration, gonadotropin-releasing hormone (GnRH) agonists have a better safety and effectiveness profile than estrogens and anti-androgens.

March 15, 2010 — The US Food and Drug Administration (FDA) has approved a twice-yearly 22.5-mg formulation of triptorelin pamoate injection (Trelstar, Watson Pharmaceuticals, Inc) for the palliative ...

Please provide your email address to receive an email when new articles are posted on . The addition of a luteinizing hormone-releasing analog to chemotherapy preserved long-term ovarian function in ...

Triptorelin market value is predicted to reach USD 1.49 billion by 2032, according to a new research report by Global Market Insights Inc. Rising awareness about precocious puberty is a key driver ...

Nodal Stage Classification for Breast Carcinoma: Improving Interobserver Reproducibility Through Standardized Histologic Criteria and Image-Based Training Prospectively collected hormonal data were ...

Details concerning the Triptorelin Pamoate for Injectable Suspension medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ...

The Triptorelin Market is expected to be worth around US$ 955.50 million in 2023. Industry is predicted to expand at a 5% CAGR from 2023 to 2033, powered by the rising prevalence of endometriosis ...